MTPH.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 mar 2023 @ 17:16):

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally...

Stats
Dagens volum	1.38M
Gjennomsnittsvolum	38 925.00
Markedsverdi	31.20M
EPS	£0 ( 2023-09-12 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.220
ATR14	£3.89 (91.46%)

Volum Korrelasjon

Lang: -0.16 (neutral)

Kort: -0.24 (neutral)

Signal:(10.581) Neutral

Midatech Pharma PLC Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Midatech Pharma PLC Korrelasjon - Valuta/Råvare

-0.69
( moderate negative )

0.52
( weak )

-0.61
( weak negative )

-0.09
( neutral )

0.22
( neutral )

Midatech Pharma PLC Økonomi

Annual	2022
Omsetning:	£699 000
Bruttogevinst:	£-4.41M (-631.19 %)
EPS:	£0

FY	2022
Omsetning:	£699 000
Bruttogevinst:	£-4.41M (-631.19 %)
EPS:	£0

FY	2021
Omsetning:	£578 000
Bruttogevinst:	£-4.08M (-705.19 %)
EPS:	£-0.0700

FY	2020
Omsetning:	£180 000
Bruttogevinst:	£-5.89M (-3 271.11 %)
EPS:	£-10.40

Financial Reports:

No articles found.

Midatech Pharma PLC

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.